Why Investors Shouldn't Be Surprised By Evolus, Inc.'s (NASDAQ:EOLS) 27% Share Price Surge
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus, Inc. (EOLS): Is It One of Caligan Partners' Top Holdings Now?
Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Evolus (EOLS) and Humana (HUM)
Evolus, Inc. (NASDAQ:EOLS) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
A Quick Look at Today's Ratings for Evolus(EOLS.US), With a Forecast Between $16 to $27
Evolus, Inc.'s (NASDAQ:EOLS) Shares Climb 27% But Its Business Is Yet to Catch Up
